Our Mission
We are developing new classes of therapeutics that address significant, unmet clinical needs. We are leveraging the discovery of Renalase made at Yale University and translating its unique properties to treat acute pancreatitis and associated pain, acute kidney injury, and difficult-to-cure cancers.
Therapeutic Areas
Three distinct pathways, one groundbreaking platform
Acute Pancreatitis & Pain
Developing RT-1002, a peptide mimetic of Renalase, to treat acute pancreatitis and associated pain, with Phase 1 with Proof-of-Mechanism (POM) for inflammation and pain planned for 2H2027.
Acute Kidney Injury
Leveraging Renalase's cell protective properties to treat ischemic and non-ischemic acute kidney injury.
Difficult-to-Cure Cancers
Blocking dysregulated renalase expression to treat and manage difficult-to-cure cancers.
The Path to Renalase Therapeutics
Discovery & Breakthrough
Renalase was discovered by Dr. Gary Désir, Paul B. Beeson Professor of Medicine at Yale University and former Chairman of Medicine (2013-2025). For the last 2 decades, his discovery has inspired a growing global community of scientists and physicians seeking to understand the role of Renalase in promoting cell survival and tissue repair, and regulating the immune system.
Protective Properties
Renalase (RNLS) is an ancient, highly conserved protein that performs essential functions due to its evolutionary history and remarkable sequence preservation. Renalase contains two well-studied, highly conserved domains. One is responsible for the oxidation of intracellular NADH. The other interacts with PMCA4b, a Plasma Membrane Calcium ATPase, and activates specific intracellular signals that promote survival in both in vitro and in vivo models of acute organ injury. We have identified the signaling module of Renalase, which is contained within a short, highly conserved peptide that mimics renalase's cytoprotective properties.
Extensive research in preclinical models and humans has shown that both Renalase and its signaling peptide are essential and potent immunomodulators that protect organs from damage such as ischemic and toxic injury, and aid in tissue repair. Additionally, they both exhibit non-opioid pain-relief properties.
Renalase in Cancer
Cancer cells can hijack the Renalase signaling pathway to survive and hide from the immune system. Dysregulated renalase production and secretion is associated with poor outcomes in patients with cancer.
Patients with low levels of Renalase survive 3x longer in cases of difficult-to-cure cancers.
Organ Protection
Activation of the Renalase pathway promotes organ protection and recovery from injury, and alleviates pain and inflammation.
Cancer Treatment
Blocking the Renalase Pathway slows and halts the progression of many forms of difficult-to-cure cancers.
Pipeline Development
REMED has begun the IND-enabling studies for RT-1002, a peptide mimetic of Renalase, for the treatment of acute pancreatitis and associated pain.
RT-1002
Acute Pancreatitis Treatment
Acute Pancreatitis is the leading cause of disease specific gastrointestinal hospital admissions, with no indicated FDA approved treatments.
Our lead therapeutic candidate targets all facets of acute pancreatitis. RT-1002 leverages the Renalase pathway's ability to promote organ recovery, control inflammation and provide non-opioid pain relief.
IND Studies
Ongoing
Investigational New Drug studies currently in progress
Phase 1 Clinical Trial
Planned 2H2027
First-in-human studies to evaluate safety and tolerability, confirm anti-inflammatory properties and establish a Proof-of-Mechanism for pain